Literature DB >> 24830793

Five-year follow-up of left ventricular diastolic function in systemic sclerosis patients: determinants of mortality and disease progression.

Réka Faludi1, Gyöngyvér Költő2, Barbara Bartos3, Georgina Csima4, László Czirják5, András Komócsi4.   

Abstract

OBJECTIVES: In systemic sclerosis (SSc), left ventricular diastolic dysfunction reflects primary myocardial involvement of the disease. We aimed to assess the abnormalities of the diastolic function, analyze the characteristics of the disease progression, and investigate the prognostic value of diastolic dysfunction in SSc patients. PATIENTS AND METHODS: A total of 34 SSc patients (57 ± 12 years, 31 female) were involved in the study. The following traditional or tissue Doppler parameters of left ventricular diastolic function were obtained: E/A, lateral E', E/E', left ventricular mass index (LVM index), and maximal left atrial (LA) volume index. Measurements were repeated after 5.5 years.
RESULTS: At baseline, diastolic dysfunction was found in 62% of the SSc patients. Follow-up time was 5.4 ± 1.2 years. A total of 6 patients died of heart failure. In univariate Cox regression analysis, age (HR = 1.08, p < 0.05), LVM index (HR = 1.07, p < 0.01), lateral E' (HR = 1.57, p = 0.05), and LA volume index (HR = 1.11, p < 0.01) were predictors of survival. During the follow-up, significant increase in LA volume index (27.5 ± 9.7 vs. 35.4 ± 10.6 cm(3)/m(2), p < 0.001) and E/E' was found (7.6 ± 2.5 vs. 8.7 ± 3.8, p < 0.05) while E' did not change (9.6 ± 2.6 vs. 9.2 ± 1.9 cm/s, NS). The increase in LA volume index showed positive correlation (r = 0.46, p < 0.05) while the decrease in E' values showed negative correlation (r = -0.54, p < 0.01) with the duration of the SSc.
CONCLUSION: In SSc patients, left ventricular diastolic dysfunction is highly prevalent and is associated with increased risk of mortality. Our data suggest that in the advanced phase of the disease, the myocardial fibrotic processes burns out while the increase of the filling pressure progresses continuously.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diastolic dysfunction; Disease progression; Follow-up; Mortality; Myocardial fibrosis; Survival; Systemic sclerosis; Tissue Doppler imaging

Mesh:

Year:  2014        PMID: 24830793     DOI: 10.1016/j.semarthrit.2014.04.001

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  12 in total

1.  Clinical characteristics and survival of systemic sclerosis patients with pulmonary hypertension and elevated wedge pressure: Observations from the PHAROS cohort.

Authors:  Matthew R Lammi; Lesley A Saketkoo; Jessica K Gordon; Paula Lauto; Karen Fagan; Virginia D Steen
Journal:  Respirology       Date:  2017-05-12       Impact factor: 6.424

Review 2.  Update on assessment and management of primary cardiac involvement in systemic sclerosis.

Authors:  Vasiliki-Kalliopi Bournia; Christos Tountas; Athanase D Protogerou; Stylianos Panopoulos; Sophie Mavrogeni; Petros P Sfikakis
Journal:  J Scleroderma Relat Disord       Date:  2018-04-04

3.  Diastolic Dysfunction in Systemic Sclerosis: Risk Factors and Impact on Mortality.

Authors:  Alicia M Hinze; Jamie Perin; Adrianne Woods; Laura K Hummers; Fredrick M Wigley; Monica Mukherjee; Ami A Shah
Journal:  Arthritis Rheumatol       Date:  2022-03-30       Impact factor: 15.483

4.  Cardiac involvement in systemic sclerosis: differences between clinical subsets and influence on survival.

Authors:  Andreu Fernández-Codina; Carmen Pilar Simeón-Aznar; Iago Pinal-Fernandez; José Rodríguez-Palomares; Maria Nazarena Pizzi; Cristina Eve Hidalgo; Alfredo Guillén-Del Castillo; Francisco Javier Prado-Galbarro; Antonio Sarria-Santamera; Vicent Fonollosa-Plà; Miquel Vilardell-Tarrés
Journal:  Rheumatol Int       Date:  2015-10-25       Impact factor: 2.631

5.  Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study.

Authors:  Veronika K Jaeger; Elina G Wirz; Yannick Allanore; Philipp Rossbach; Gabriela Riemekasten; Eric Hachulla; Oliver Distler; Paolo Airò; Patricia E Carreira; Alexandra Balbir Gurman; Mohammed Tikly; Serena Vettori; Nemanja Damjanov; Ulf Müller-Ladner; Jörg H W Distler; Mangtao Li; Ulrich A Walker
Journal:  PLoS One       Date:  2016-10-05       Impact factor: 3.240

6.  Autoimmune myocarditis in systemic sclerosis: an unusual form of scleroderma heart disease presentation.

Authors:  Ana Rita Ramalho; Susana Costa; Francisco Silva; Paulo Donato; Fátima Franco; Guilherme Mariano Pêgo
Journal:  ESC Heart Fail       Date:  2017-04-22

7.  Poor survival in patients with scleroderma and pulmonary hypertension due to heart failure with preserved ejection fraction.

Authors:  Khalil I Bourji; Benjamin W Kelemen; Stephen C Mathai; Rachel L Damico; Todd M Kolb; Valentina Mercurio; Franco Cozzi; Ryan J Tedford; Paul M Hassoun
Journal:  Pulm Circ       Date:  2017-03-27       Impact factor: 3.017

8.  Left atrial stiffness is superior to volume and strain parameters in predicting elevated NT-proBNP levels in systemic sclerosis patients.

Authors:  Adél Porpáczy; Ágnes Nógrádi; Vivien Vértes; Margit Tőkés-Füzesi; László Czirják; András Komócsi; Réka Faludi
Journal:  Int J Cardiovasc Imaging       Date:  2019-05-15       Impact factor: 2.357

9.  Systolic Dysfunction in Systemic Sclerosis: Prevalence and Prognostic Implications.

Authors:  Anders H Tennøe; Klaus Murbræch; Johanna C Andreassen; Håvard Fretheim; Øyvind Midtvedt; Torhild Garen; Håvard Dalen; Einar Gude; Arne Andreassen; Svend Aakhus; Øyvind Molberg; Anna-Maria Hoffmann-Vold
Journal:  ACR Open Rheumatol       Date:  2019-05-31

10.  Cardiac reserve by 6-minute walk stress echocardiography in systemic sclerosis.

Authors:  Miharu Arase; Kenya Kusunose; Sae Morita; Natsumi Yamaguchi; Yukina Hirata; Susumu Nishio; Yuichiro Okushi; Takayuki Ise; Takeshi Tobiume; Koji Yamaguchi; Daiju Fukuda; Shusuke Yagi; Hirotsugu Yamada; Takeshi Soeki; Tetsuzo Wakatsuki; Masataka Sata
Journal:  Open Heart       Date:  2021-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.